Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056238 · ClinicalTrials.gov registry record · Phase 2
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
A Phase 2 study of Stroke and Neurologic Diseases, General, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT00056238: Completed Phase 2 study of Stroke and Neurologic Diseases, General, sponsored by Bellus Health Inc. - a GSK company.
NCT00056238 is a Phase 2 study of Stroke and Neurologic Diseases, General that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 30 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00056238, a Phase 2 study of Stroke and Neurologic Diseases, General, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
Conditions Studied
Interventions
- DRUG NC-758 (Anti amyloidotic [Aß] agent)
Study Locations (5)
Kentucky
- University of Kentucky - Lexington
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Columbia University - New York
Ohio
- University of Cincinnati - Cincinnati
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-02 |
| Phase | Phase 2 |
What the finished NCT00056238 record still lists
NCT00056238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which NC-758 (Anti amyloidotic [Aß] agent) is the first listed.
NCT00056238 lists 5 locations in 5 states (Kentucky, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT00056238 about?
NCT00056238 is a clinical study titled "Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy". The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
What is the current status of trial NCT00056238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-02.
What conditions does trial NCT00056238 study?
This clinical trial studies the following conditions: Stroke, Neurologic Diseases, General.
What interventions are being tested in trial NCT00056238?
The interventions under investigation include: NC-758 (Anti amyloidotic [Aß] agent) (DRUG).
Who is sponsoring clinical trial NCT00056238?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00056238 being conducted?
This trial has 5 study locations across Kentucky, Massachusetts, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00056238's enrollment target sits among peer trials
30 301st of 454 higher than 137 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia